Summary of The Medicines Company (NASDAQ:MDCO) Ratings as of May 17, 2018

May 17, 2018 - By Alma Kearns

The Medicines Company (NASDAQ:MDCO) Corporate Logo
Big Money Sentiment increased to 1.25 in 2017 Q4. It has change of 0.47, from 2017Q3’s 0.78. The ratio increased due to The Medicines Company positioning: 26 sold and 51 reduced. 28 funds bought stakes and 68 increased stakes. Investors holded 85.15 million in 2017Q3 but now own 89.44 million shares or 5.03% more.
Old West Invest Mngmt Limited Liability holds 0.12% or 7,806 shs. 651 are held by X Mngmt Co Limited Company. Bridger Limited Liability Corporation invested 5.07% in The Medicines Company (NASDAQ:MDCO). Royal Natl Bank Of Canada stated it has 1,344 shs or 0% of all its holdings. Clearline Cap L P reported 99,891 shs. Minnesota-based Ameriprise Fincl has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Guggenheim Cap Ltd Liability Corp stated it has 0.01% in The Medicines Company (NASDAQ:MDCO). Tower Research Cap Ltd Co (Trc) reported 202 shs. Arizona State Retirement System reported 107,819 shs. California State Teachers Retirement Sys has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Credit Suisse Ag holds 0% or 75,641 shs in its capital. State Street holds 0% or 2.17M shs in its capital. Granahan Ma holds 59,716 shs or 0.13% of its capital. Price T Rowe Assocs Md holds 76,726 shs or 0% of its capital. Wellington Mgmt Group Limited Liability Partnership holds 0.06% of its capital in The Medicines Company (NASDAQ:MDCO) for 10.19 million shs.

The Medicines Company had 3 insider sales and 1 buy since December 7, 2017. This’s net activity of $783,400. Shares for $574,200 were sold by KESSLER ARMIN M on Tuesday, January 16. On Friday, December 15 $3.71M worth of The Medicines Company (NASDAQ:MDCO) was sold by MEANWELL CLIVE. 200,000 The Medicines Company (NASDAQ:MDCO) shs with value of $5.31 million were bought by ESHELMAN FREDRIC N.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Total analysts of 3 have positions in Medicines Co (NASDAQ:MDCO) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 29, 2017 according to StockzIntelligence Inc Medicines Co has 6 analyst reports. On Monday, January 15 the stock has “Buy” rating by Oppenheimer. In Thursday, March 22 report Oppenheimer maintained the stock with “Buy” rating. In Wednesday, November 29 report Oppenheimer upgraded the stock to “Buy” rating. On Thursday, February 22 Oppenheimer maintained the shares of MDCO in report with “Hold” rating. In Monday, January 22 report Citigroup upgraded it to “Buy” rating and $40.0 target. Listed here are The Medicines Company (NASDAQ:MDCO) PTs and latest ratings.

22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain
29/11/2017 Broker: Oppenheimer Rating: Buy New Target: $50.0 Upgrade

MDCO touched $32.2 during the last trading session after $0.07 change.The Medicines Company has volume of 288,319 shares. Since May 17, 2017 MDCO has declined 34.73% and is downtrending. MDCO underperformed by 46.28% the S&P500.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The firm is worth $2.37 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.Currently it has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

For more The Medicines Company (NASDAQ:MDCO) news announced briefly go to: Fool.com, Streetinsider.com, Fool.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” announced on May 17, 2018, “Einhorn’s Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more…) – 13F” on May 15, 2018, “Alnylam Looks Forward” with a publish date: May 08, 2018, “Medicines Co. (MDCO) ORION-1 Phase II Study Shows Significant Reductions in Potentially Harmful Subtypes of Bad …” and the last “The Medicines (MDCO) Q1 2018 Results – Earnings Call Transcript” with publication date: April 25, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.